PolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary

Polypid

12/08/2026 14:33

PolyPid Ltd PYPD.OQ reported a quarterly adjusted loss of 35 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -78 cents.  The mean expectation of four analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -49 cents to -32 cents per share.
Reported revenue was zero​; analysts expected zero. 
PolyPid Ltd's reported EPS for the quarter was a loss of 35 cents​.
The company reported a quarterly loss of $7.85 million.
PolyPid Ltd shares had fallen by 6.9% this quarter and gained 9.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 9.6% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for PolyPid Ltd is $12.50, about 62.2% above its last closing price of $4.73
This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.38
-0.35
Beat
Mar. 31 2026 
-0.43
-0.35
Beat
Dec. 31 2025 
-0.33
-0.41
Missed
Sep. 30 2025 
-0.52
-0.37
Beat